Literature DB >> 26056267

Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.

Tadaki Suzuki1, Akira Kawaguchi1, Akira Ainai2, Shin-ichi Tamura1, Ryo Ito1, Pretty Multihartina3, Vivi Setiawaty3, Krisna Nur Andriana Pangesti3, Takato Odagiri4, Masato Tashiro4, Hideki Hasegawa5.   

Abstract

Secretory IgA (S-IgA) antibodies, the major contributors to humoral mucosal immunity to influenza virus infection, are polymeric Igs present in many external secretions. In the present study, the quaternary structures of human S-IgA induced in nasal mucosa after administration of intranasal inactivated influenza vaccines were characterized in relation to neutralization potency against influenza A viruses. Human nasal IgA antibodies have been shown to contain at least five quaternary structures. Direct and real-time visualization of S-IgA using high-speed atomic force microscopy (AFM) demonstrated that trimeric and tetrameric S-IgA had six and eight antigen-binding sites, respectively, and that these structures exhibited large-scale asynchronous conformational changes while capturing influenza HA antigens in solution. Furthermore, trimeric, tetrameric, and larger polymeric structures, which are minor fractions in human nasal IgA, displayed increased neutralizing potency against influenza A viruses compared with dimeric S-IgA, suggesting that the larger polymeric than dimeric forms of S-IgA play some important roles in protection against influenza A virus infection in the human upper respiratory tract.

Entities:  

Keywords:  high-speed atomic force microscopy; influenza virus; intranasal inactivated influenza vaccine; secretory IgA

Mesh:

Substances:

Year:  2015        PMID: 26056267      PMCID: PMC4485102          DOI: 10.1073/pnas.1503885112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  The systemic and mucosal immune response of humans to influenza A virus.

Authors:  B R Murphy; M L Clements
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

2.  In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA.

Authors:  K B Renegar; G D Jackson; J Mestecky
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

Review 3.  Combatting infectious diseases; nanotechnology as a platform for rational vaccine design.

Authors:  Elly van Riet; Akira Ainai; Tadaki Suzuki; Gideon Kersten; Hideki Hasegawa
Journal:  Adv Drug Deliv Rev       Date:  2014-05-23       Impact factor: 15.470

4.  Homogenous IgA monomers, dimers, trimers and tetramers from the same IgA myeloma serum.

Authors:  J P Vaerman; A Langendries; C Vander Maelen
Journal:  Immunol Invest       Date:  1995-05       Impact factor: 3.657

5.  Immunoglobulin A (IgA).

Authors:  J Mestecky; M Kilian
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

6.  The stoichiometry of J chain in human secretory IgA.

Authors:  M S Halpern; M E Koshland
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

7.  Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents.

Authors:  M A Phelan; R E Mayner; D J Bucher; F A Ennis
Journal:  J Biol Stand       Date:  1980

8.  Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.

Authors:  S Kadowaki; Z Chen; H Asanuma; C Aizawa; T Kurata; S Tamura
Journal:  Vaccine       Date:  2000-06-15       Impact factor: 3.641

9.  Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.

Authors:  Kathryn B Renegar; Parker A Small; Lou G Boykins; Peter F Wright
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

10.  Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG.

Authors:  H P Taylor; N J Dimmock
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  41 in total

1.  IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Authors:  Yoshihiko Terauchi; Kaori Sano; Akira Ainai; Shinji Saito; Yuki Taga; Kiyoko Ogawa-Goto; Shin-Ichi Tamura; Takato Odagiri; Masato Tashiro; Mikiya Fujieda; Tadaki Suzuki; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

2.  The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.

Authors:  Atsushi Kawai; Yasuyuki Yamamoto; Takuto Nogimori; Kohei Takeshita; Takuya Yamamoto; Yasuo Yoshioka
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

3.  Mucosal Antibody Response to SARS-CoV-2 in Paediatric and Adult Patients: A Longitudinal Study.

Authors:  Renee W Y Chan; Kate C C Chan; Grace C Y Lui; Joseph G S Tsun; Kathy Y Y Chan; Jasmine S K Yip; Shaojun Liu; Michelle W L Yu; Rita W Y Ng; Kelvin K L Chong; Maggie H Wang; Paul K S Chan; Albert M Li; Hugh Simon Lam
Journal:  Pathogens       Date:  2022-03-24

4.  Identification of antigens recognized by salivary IgA using microbial protein microarrays.

Authors:  Koji Hamuro; Hiroshi Saito; Takao Saito; Noriyuki Kohda
Journal:  Biosci Microbiota Food Health       Date:  2022-06-06

5.  Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.

Authors:  Kosuke Okuya; Reiko Yoshida; Rashid Manzoor; Shinji Saito; Tadaki Suzuki; Michihito Sasaki; Takeshi Saito; Yurie Kida; Akina Mori-Kajihara; Tatsunari Kondoh; Masahiro Sato; Masahiro Kajihara; Hiroko Miyamoto; Osamu Ichii; Hideaki Higashi; Ayato Takada
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

Review 6.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

Review 7.  IgA Nephropathy: An Interesting Autoimmune Kidney Disease.

Authors:  Arun Rajasekaran; Bruce A Julian; Dana V Rizk
Journal:  Am J Med Sci       Date:  2020-10-08       Impact factor: 2.378

8.  Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.

Authors:  Chunhong Dong; Ye Wang; Gilbert X Gonzalez; Yao Ma; Yufeng Song; Shelly Wang; Sang-Moo Kang; Richard W Compans; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 11.205

9.  Ingestion of Okinawa Island Vegetables Increases IgA Levels and Prevents the Spread of Influenza RNA Viruses.

Authors:  Kenji Gonda; Hideto Kanazawa; Goki Maeda; Chisa Matayoshi; Naoto Hirose; Yukiteru Katsumoto; Koji Kono; Seiichi Takenoshita
Journal:  Nutrients       Date:  2021-05-22       Impact factor: 5.717

10.  Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein.

Authors:  C Joaquín Cáceres; Stivalis Cardenas-Garcia; Aarti Jain; L Claire Gay; Silvia Carnaccini; Brittany Seibert; Lucas M Ferreri; Ginger Geiger; Algimantas Jasinskas; Rie Nakajima; Daniela S Rajao; Irina Isakova-Sivak; Larisa Rudenko; Amy L Vincent; D Huw Davies; Daniel R Perez
Journal:  Vaccines (Basel)       Date:  2021-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.